A Dark Vector Cognition product

Bio-Techne 10-Q/A 2026-09-30

TECH · CIK 842023 · Form 10-Q/A · Period ended September 30, 2026 · Filed November 12, 2026

Revenue rose 4.6% to $300 million. Operating margin was 12.2%, against 16.6% a year earlier. Net income was $28.3 million.

8 sections, 111K characters. Original on sec.gov · ·

Risk FactorsBusiness

Key numbers
MeasureQuarter ended Sep 30, 2026Quarter ended Sep 30, 2025Change
Revenue$300M$287M+4.6%
Operating income$36.6M$47.7M-23.2%
Net income$28.3M$38.2M-25.9%
Diluted EPS$0.18$0.24-25.0%
Free cash flow*$67.2M$22.2M+202%
Cash and equivalents$350Mn/an/a
Operating margin*12.2%16.6%-4.4 pts

From the XBRL facts tagged to this filing; both columns are as reported in this filing. * Computed by filings.tools: free cash flow is operating cash flow less capital spending; operating margin is operating income over revenue.

The 57 tables in this filing as one CSV, figures in aligned columns. For subscribers: paste your API key. One API call. Plans from $19 a month, see pricing.

Cover and table of contents

​

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 10-Q/A

(Amendment No. 1)

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2026**, or**

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 0-17272

BIO-TECHNE CORPORATION

(Exact name of registrant as specified in its charter)

Minnesota41-1427402
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
614 McKinley Place N.E. Minneapolis**,** MN 55413(612) 379-8854
(Address of principal executive offices) (Zip Code)(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Exchange Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.01 par valueTECHThe NASDAQ Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer☒Accelerated filer☐
Non-accelerated filer☐Smaller reporting company☐
Emerging growth company☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the Registrant is a shell company (as defined in Exchange Act Rule 12b- 2). ☐ Yes ☒ No

At November 2, 2026, 157,090,727 shares of the Company's Common Stock (par value $0.01) were outstanding.

​

EXPLANATORY NOTE

Bio-Techne Corporate is filing this Amendment No. 1 on Form 10-Q/A (the “Amendment”) to its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, filed with the Securities and Exchange Commission on November 6, 2026 (the “Original Report”), solely to correct the signature page to the Original Report, which inadvertently omitted the conformed electronic signatures.

Except for the adding of the conformed electronic signatures, no other changes have been made to the Original Report. This Amendment does not reflect any subsequent events occurring after the original filing date of the Original Report or modify or update in any way disclosures made in the Original Report.

​

​

​

​

​

​

TABLE OF CONTENTS

​

Page
PART I. FINANCIAL INFORMATION
Item 1.Condensed Consolidated Financial Statements (Unaudited)1
Condensed Consolidated Statements of Earnings and Comprehensive Income1
​Condensed Consolidated Balance Sheets2
​Condensed Consolidated Statements of Cash Flows3
​Condensed Consolidated Statements of Stockholders’ Equity4
​Notes to Condensed Consolidated Financial Statements5
​Note 1. Basis of Presentation and Summary of Significant Accounting Policies5
​Note 2. Revenue Recognition6
​Note 3. Selected Balance Sheet Information8
​Note 4. Fair Value Measurements9
​Note 5. Debt and Other Financing Arrangements12
​Note 6. Leases12
​Note 7. Supplemental Equity and Accumulated Other Comprehensive Income (Loss)14
​Note 8. Earnings Per Share15
​Note 9. Share-based Compensation and Other Benefit Plans15
​Note 10. Other Income/(Expense)16
​Note 11. Income Taxes16
​Note 12. Segment Information16
​Note 13. Restructuring17
​Note 14. Subsequent Events19
​​​
Item 2.Management's Discussion and Analysis of Financial Condition and Results of Operations20
Item 3.Quantitative and Qualitative Disclosures about Market Risk27
Item 4.Controls and Procedures27
PART II: OTHER INFORMATION
Item 1.Legal Proceedings27
Item 1A.Risk Factors27
Item 2.Unregistered Sales of Equity Securities and Use of Proceeds27
Item 3.Defaults Upon Senior Securities28
Item 4.Mine Safety Disclosures28
Item 5.Other Information28
Item 6.Exhibits29
​SIGNATURES30

​

​

​

​

​

​

PART I. FINANCIAL INFORMATION

Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS

AND COMPREHENSIVE INCOME

Bio-Techne Corporation and Subsidiaries

(in thousands, except per share data)

(unaudited)

​

​​​​​​​​
​​Quarter Ended​
​​September 30,​
​​2026​2025​
Net sales​$299,712​$286,555​
Cost of sales​103,089​98,443​
Gross margin​196,623​188,112​
​​​​​​​​
Operating expenses:​​​​​​
Selling, general and administrative​133,679​116,213​
Research and development​26,341​24,241​
Total operating expenses​160,020​140,454​
Operating income​36,603​47,658​
​​​​​​​​
Other income (expense)​​(1,910)​​333​
Earnings before income taxes​34,693​47,991​
Income taxes​6,400​9,806​
Net earnings​$28,293​$38,185​
Other comprehensive income (loss):​​​​​
Foreign currency translation income (loss)​(617)​(2,850)​
Unrealized losses on derivative instruments​—​(1,665)​
Other comprehensive income (loss)​(617)​(4,515)​
Comprehensive income​$27,676​$33,670​
​​​​​​​​
Earnings per share:​​​​​​​
Basic​$0.18​$0.25​
Diluted​$0.18​$0.24​
​​​​​​​​
Weighted average common shares outstanding:​​​​​
Basic​156,800​155,464​
Diluted​157,928​156,362​

​

See Notes to Condensed Consolidated Financial Statements.

​

CONDENSED CONSOLIDATED BALANCE SHEETS

Bio-Techne Corporation and Subsidiaries

(in thousands, except share and per share data)

​

​​​​​​​
​​ ​ ​September 30,​​​
​​2026​June 30,
​​(unaudited)​2026
ASSETS​​​​
Current assets:​​​​
Cash and cash equivalents​$350,036​$264,712
Accounts receivable, less allowances of $4,832 and $4,644, respectively​203,058​216,585
Inventories​197,667​195,744
Other current assets​​74,069​67,360
Total current assets​824,830​744,401
​​​​​​​
Property and equipment, net​227,764​231,836
Right-of-use assets​64,408​67,333
Goodwill​972,074​975,355
Intangible assets, net​287,035​303,465
Other assets​260,709​264,336
Total assets​$2,636,820​$2,586,726
LIABILITIES AND SHAREHOLDERS’ EQUITY​​​​
Current liabilities:​​​​
Trade accounts payable​$30,996​$26,699
Salaries, wages and related accruals​44,347​57,918
Accrued expenses​19,751​20,458
Short-term debt obligations​​200,000​​—
Contract liabilities​31,758​36,072
Income taxes payable​2,708​3,593
Operating lease liabilities - current​14,992​14,935
Other current liabilities​16,717​4,025
Total current liabilities​361,269​163,700
​​​​​​​
Deferred income taxes​23,506​19,308
Long-term debt obligations​—​200,000
Operating lease liabilities​70,563​74,152
Other long-term liabilities​15,793​21,345
​​​​​
Shareholders’ equity:​​​​​​
Undesignated capital stock, par value $.01 per share; authorized 5,000,000 shares; none issued or outstanding​—​—
Common stock, par value $.01 per share; authorized 400,000,000; issued and outstanding 157,053,885 and 156,095,113 respectively​1,571​1,561
Additional paid-in capital​1,082,629​1,033,052
Retained earnings​1,152,686​1,144,188
Accumulated other comprehensive loss​(71,197)​(70,580)
Total shareholders’ equity​2,165,689​2,108,221
Total liabilities and shareholders’ equity​$2,636,820​$2,586,726

​

See Notes to Condensed Consolidated Financial Statements.

​

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

Bio-Techne Corporation and Subsidiaries

(in thousands)

(unaudited)

​

​​​​​​​
​​ ​ ​Quarter Ended
​​September 30,
​​2026​2025
CASH FLOWS FROM OPERATING ACTIVITIES:​​​​
Net earnings​$28,293​$38,185
Adjustments to reconcile net earnings to net cash provided by operating activities:​​​​
Depreciation and amortization​23,726​24,340
Deferred income taxes​2,444​5,275
Stock-based compensation expense​13,407​11,682
(Gain) Loss on equity method investment​​(1,776)​​(294)
(Gain) Loss on investments​​(325)​​(2,054)
Leases, net​(710)​(912)
Recovery of assets held-for-sale​​—​​(6,789)
Other operating activity​1,153​1,001
Change in operating assets and operating liabilities:​​​​
Trade accounts and other receivables, net​13,329​22,392
Inventories​(2,508)​(14,002)
Prepaid expenses​(1,489)​380
Trade accounts payable, accrued expenses, contract liabilities, and other​14,315​(2,115)
Salaries, wages and related accruals​(13,545)​(22,101)
Income taxes payable​(3,201)​(27,403)
Net cash provided by operating activities​73,113​27,585
​​​​​​​
CASH FLOWS FROM INVESTING ACTIVITIES:​​​​
Additions to property and equipment​(5,917)​(5,363)
Distributions from Wilson Wolf​​1,990​​1,351
Proceeds from sale of assets held-for-sale​​—​​4,617
Net cash used in investing activities​(3,927)​605
​​​​​​​
CASH FLOWS FROM FINANCING ACTIVITIES:​​​​
Cash dividends​(12,559)​(12,444)
Proceeds from stock option exercises​36,180​23,495
Repurchases of common stock​—​(24)
Repayments of long-term debt​—​(46,000)
Taxes paid on RSUs and net share settlements​​(7,236)​​(9,231)
Net cash used in financing activities​16,385​(44,204)
​​​​​​​
Effect of exchange rate changes on cash and cash equivalents​(247)​(1,210)
Net change in cash and cash equivalents​85,324​(17,224)
Cash and cash equivalents at beginning of period​264,712​162,186
Cash and cash equivalents at end of period​$350,036​$144,962
​​​​​​​
Supplemental disclosure of cash flow information:​​​​​​
Cash paid for income taxes​$6,822​$30,812

Showing the first 8K of 71K characters. Open the full section

Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL

CONDITION AND RESULTS OF OPERATIONS

The following management discussion and analysis (“MD&A”) provides information that we believe is useful in understanding our operating results, cash flows and financial condition. We provide quantitative information about the material sales drivers including the effect of acquisitions and changes in foreign currency at the corporate and segment level. We also provide quantitative information about discrete tax items and other significant factors we believe are useful for understanding our results. The MD&A should be read in conjunction with both the unaudited condensed consolidated financial information and related notes included in this Form 10-Q, and MD&A of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended June 30, 2026. This discussion contains various “Non-GAAP Financial Measures” and also contains various “Forward-Looking Statements” within the meaning of the Private Securities Litigation Reform Act of 1995. We refer readers to the statements entitled “Non-GAAP Financial Measures” and “Forward-Looking Information and Cautionary Statements” located at the end of Item 2 of this report.

OVERVIEW

Bio-Techne and its subsidiaries, collectively doing business as Bio-Techne Corporation (Bio-Techne, we, our, us or the Company) develop, manufacture and sell biotechnology reagents, instruments and services for the research and clinical diagnostic markets worldwide. With our deep product portfolio and application expertise, we sell integral components of scientific investigations into biological processes and molecular diagnostics, revealing the nature, diagnosis, etiology and progression of specific diseases. Our products aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses.

We are committed to providing the life sciences community with innovative, high-quality scientific tools that allow our customers to make extraordinary discoveries and treat and diagnose diseases. We intend to build on Bio-Techne’s past accomplishments, high product quality reputation and sound financial position by executing strategies that position us to serve as the standard for biological content in the research market, and to leverage that leadership position to enter the diagnostics and other adjacent markets. The Company’s strategic pillars for long-term growth and profitability are grow and leverage the core, capitalize on high potential markets, market expansion through innovation and acquisition, deliver best-in-class customer experience, and develop people through a transformative culture.

Our Protein Sciences segment is a leading developer and manufacturer of high-quality purified proteins and reagent solutions, most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. This segment also includes protein analysis solutions that offer researchers efficient and streamlined options for automated western blot and multiplexed ELISA workflow. Our Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers, as well as a portfolio of clinical molecular diagnostic oncology assays. This segment also manufactures and sells advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use.

PENDING MERGER WITH MERCK KGAA, DARMSTADT, GERMANY

In June 2026, the Company entered into the Agreement and Plan of Merger (the “Merger Agreement”), with Merck KGaA, Darmstadt, Germany, a German corporation with general partners (“Parent”), and EMD Holdings NewCo, Inc., a Minnesota corporation and a wholly-owned subsidiary of Parent (“Merger Sub”). The Merger Agreement provides that, on the terms and subject to the conditions of the Merger Agreement, Merger Sub will merge with and into the Company (the “Merger”), with the Company surviving as a wholly-owned subsidiary of Parent. On September 23, 2026, the Company’s shareholders voted to approve the Merger Agreement under which Parent proposes to acquire the Company. The Merger is expected to close by late 2026 or early 2027, subject to satisfaction of additional customary closing conditions. For further information regarding this contingency, refer to Note 1 of the Company’s Annual Report on Form 10-K for the year ended June 30, 2026.

RESULTS OF OPERATIONS

Net Sales

Consolidated net sales for the quarter ended September 30, 2026 were $299.7 million, an increase of 5% compared to the same prior year period. Organic revenue for the quarter ended September 30, 2026 increased 7% compared to the prior year, with foreign currency exchange having an immaterial impact and business held-for-sale having an unfavorable impact of 2%.

Gross Margins

Consolidated gross margin for the quarter ended September 30, 2026 was 65.6% compared to 65.6% for the same prior year period. Excluding the impact of amortization of intangibles, stock-based compensation expense, restructuring and restructuring-related costs, and the impact of businesses held-for-sale, adjusted gross margin for the quarter ended September 30, 2026 was 69.3% compared to 70.2% for the quarter ended September 30, 2025.

A reconciliation of the reported consolidated gross margin percentages, adjusted for intangible amortization, stock compensation expense, restructuring and restructuring-related charges, and the impact of businesses held-for-sale included in Cost of sales, is as follows (in thousands):

​​​​​​​
​​Quarter Ended
​​September 30,
​​2026​2025
Total consolidated net sales​$299,712​$286,555
Business held-for-sale(1)​​—​​5,439
Revenue from recurring operations​$299,712​$281,116
​​​​​​​
Gross margin - GAAP​$196,623​$188,112
Gross margin percentage - GAAP​​65.6%​65.6
​​​​​​​
Identified adjustments:​​​​​
Amortization of intangibles$9,359​$9,439
Stock-based compensation, inclusive of employer taxes​366​​385
Restructuring and restructuring-related costs​​1,406​​2,079
Impact of business held-for-sale(1)​​—​​(2,581)
Adjusted gross margin$207,754​$197,434
Adjusted gross margin percentage(2)​​69.3%​70.2
(1)September 30, 2025 amounts relate to the Diagnostics and Spatial Biology segment business that met the held-for-sale criteria on June 30, 2025.
(2)Adjusted gross margin percentage excludes both revenue and gross margin for the business that met the held-for-sale criteria during the respective periods.

Selling, General and Administrative Expenses

Selling, general and administrative expenses increased 15% to $133.7 million for the quarter ended September 30, 2026 from the same prior year period.

Research and Development Expenses

Research and development expenses increased 9% to $26.3 million for the quarter ended September 30, 2026 from the same prior year period.

Segment Results

Protein Sciences

​​​​​​​​
​​ ​ ​Quarter Ended​
​​September 30,​
​​2026​ ​2025​ ​
Net sales (in thousands)$219,691​$202,188​
Operating margin percentage37.9%38.4%

​

The Protein Sciences segment’s net sales for the quarter ended September 30, 2026 was $219.7 million, which increased 9% compared to the same respective prior year period. Organic revenue for the segment increased 9%, and foreign currency exchange had an immaterial impact.

The operating margin was 37.9% for the quarter ended September 30, 2026 compared to 38.4% in the comparative prior year period.

Diagnostics and Spatial Biology

​

​​​​​​​​
​​ ​ ​Quarter Ended​
​​September 30,​
​​2026​ ​2025​ ​
Net sales (in thousands)$80,164​$79,458​
Operating margin percentage7.4%11.2%

The Diagnostics and Spatial Biology segment’s net sales for the quarter ended September 30, 2026 was $80.2 million, with a reported increase of 1% compared to the same respective prior year period. Organic revenue growth was 1% for the first quarter of fiscal 2027, with foreign currency exchange having an immaterial impact.

The operating margin for the segment was 7.4% for the quarter ended September 30, 2026 compared to 11.2% in the comparative prior year period.

Income Taxes

Income taxes were at an effective rate of 18.4% of consolidated earnings for the quarter ended September 30, 2026, compared to 20.4% for the same respective prior year period. The change in the Company’s tax rate for the quarter ended September 30, 2026 was driven by the mix of net income and timing of discrete items.

The forecasted tax rate as of the first fiscal quarter of 2026 before discrete items is 23.4% compared to the prior year forecasted tax rate before discrete items of 26.5%. Excluding the impact of discrete items, the Company expects the consolidated income tax rate for the remainder of fiscal 2027 to range from 23% to 27%.

​

Net Earnings

​

Non-GAAP adjusted consolidated net earnings are as follows (in thousands):

​

​​​​​​​​​
​​Quarter Ended​
​​September 30,​
​2026​2025​​
Net earnings before taxes - GAAP​ ​ ​$34,693​$47,991​​
Identified adjustments:​​​​​​​
Amortization of intangibles​14,663​15,350​​
Amortization of Wilson Wolf intangible assets​​2,490​​2,490​​
Acquisition related expenses and other​17,906​3,508​​
Certain litigation charges​​46​​2,408​​
Stock-based compensation, inclusive of employer taxes​14,757​12,096​​
Restructuring and restructuring-related costs​3,838​7,511​​
Investment loss (gain) and other non-operating loss (gain)​​799​​(2,146)​​
Impairment (Recovery) of assets held-for-sale​​—​​(6,789)​​
Impact of business held-for-sale(1)​​—​​2,573​​
Net earnings before taxes - Adjusted​$89,192​$84,992​​
Non-GAAP tax rate​21.4%22.3%​
Non-GAAP tax expense​$19,087​$18,953​​
Non-GAAP adjusted net earnings​$70,105​$66,039​​
Earnings per share - diluted - Adjusted​$0.44​$0.42​​
(1)September 30, 2025 amounts relate to the Diagnostics and Spatial Biology segment business that met the held-for-sale criteria on June 30, 2025.

Depending on the nature of discrete tax items, our reported tax rate may not be consistent on a period-to-period basis. The Company independently calculates a non-GAAP adjusted tax rate considering the impact of discrete items and jurisdictional mix of the identified

non-GAAP adjustments. The following table summarizes the reported GAAP tax rate and the effective non-GAAP adjusted tax rate for the quarters ended September 30, 2026 and 2025.

​

​​​​​​​
​​Quarter Ended
​​September 30,
​​ ​ ​2026​2025
GAAP effective tax rate18.4%​20.4%
Discrete items​5.0​​6.1​
Long-term GAAP tax rate23.4%​26.5%
Rate impact items​​​​​​
Stock based compensation(2.7)%​(2.7)%
Other​0.7​​(1.5)​
Total rate impact items(2.0)%​(4.2)%
Non-GAAP adjusted tax rate21.4%​22.3%

The difference between the reported GAAP tax rate and non-GAAP tax rate applied to the identified non-GAAP adjustments for the quarter ended September 30, 2026 is primarily a result of discrete tax items, including the tax benefit of stock option exercises.

LIQUIDITY AND CAPITAL RESOURCES

Cash and cash equivalents were $350.0 million as of September 30, 2026, compared to $264.7 million as of June 30, 2026.

The Company has a line-of-credit governed by a Credit Agreement dated August 31, 2022 that will mature on August 31, 2027. As of September 30, 2026, there is $800.0 million available on the line-of-credit. See Note 5 to the Condensed Consolidated Financial Statements for a description of the Credit Agreement.

During fiscal year 2022, the Company paid $25 million to enter into a two-part forward contract which requires the Company to purchase the full equity interest in Wilson Wolf if certain annual revenue or EBITDA thresholds are met. During fiscal year 2023, Wilson Wolf met the EBITDA target and the Company paid an additional $232 million to acquire 19.9% of Wilson Wolf. Since the first part of the forward contract has been triggered, the second part of the forward contract will automatically trigger, which requires the Company to acquire the remaining 80.1% of Wilson Wolf on December 31, 2027. The second part of the contract would be accelerated in advance of December 31, 2027 if Wilson Wolf meets certain financial milestones. As of September 30, 2026, the second milestones have not been met. The second option payment of approximately $1 billion plus potential contingent consideration is forecasted to occur between fiscal 2027 and fiscal 2028.

Management of the Company expects to be able to meet its cash and working capital requirements for operations, facility expansion, capital additions, and cash dividends for the foreseeable future, and at least the next 12 months, through currently available cash, cash generated from operations, and remaining credit available on its existing revolving line of credit.

Cash Flows From Operating Activities

The Company generated cash of $73.1 million from operating activities in the first quarter of fiscal 2027 compared to $27.6 million in the first quarter of fiscal 2026. The increase from the prior year was primarily due to changes in the timing of cash payments on certain operating assets and liabilities.

Cash Flows From Investing Activities

We continue to make investments in our business, including capital expenditures.

Capital expenditures for fixed assets for the first quarter of fiscal 2027 and 2026 were $5.9 million and $5.4 million, respectively. Capital expenditures for the remainder of fiscal 2027 are expected to be approximately $28 million. Capital expenditures are expected to be financed through currently available funds and cash generated from operating activities. Expected additions in fiscal 2027 are related to increasing capacity to meet expected sales growth across the Company.

During the first quarter of fiscal 2026, the Company received $4.6 million for assets held-for-sale. There was no comparable activity in the first quarter of fiscal 2027.

The Company received tax distributions of $2.0 million and $1.4 million from its equity method investee during the first quarter of fiscal 2027 and 2026, respectively.

Cash Flows From Financing Activities

During the first quarter of fiscal 2027 and 2026, the Company paid cash dividends of $12.6 million and $12.4 million, respectively, to all common shareholders.

Cash of $36.2 million and $23.5 million was received during the first quarter of fiscal 2027 and 2026, respectively, from the exercise of stock options.

During the first quarter of fiscal 2026, the Company made repayments of $46.0 million on its long-term debt balance. There was no comparable activity in the first quarter of fiscal 2027. The Company did not draw under its revolving line-of-credit facility during the first quarter of fiscal 2027 and 2026.

During the first quarter of fiscal 2027 and 2026, the Company paid taxes of $7.2 million and $9.2 million, respectively, related to taxes on restricted stock, restricted stock units and stock options exercised through a net share settlement.

​

CRITICAL ACCOUNTING POLICIES

The Company's significant accounting policies are discussed in the Company's Annual Report on Form 10-K for fiscal 2026 and are incorporated herein by reference. The application of certain of these policies requires judgments and estimates that can affect the results of operations and financial position of the Company. Judgments and estimates are used for, but not limited to, valuation of available-for-sale investments, inventory valuation and allowances, valuation of intangible assets and goodwill and valuation of investments in unconsolidated entities. There have been no significant changes in estimates in the quarter ended September 30, 2026 that would require disclosure nor have there been any changes to the Company's policies.

NON-GAAP FINANCIAL MEASURES

This Quarterly Report on Form 10-Q, including “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Item 2, contains financial measures that have not been calculated in accordance with accounting principles generally accepted in the U.S. (GAAP). These non-GAAP measures include:

●Organic revenue

●Adjusted gross margin

●Adjusted operating margin

●Adjusted net earnings and diluted earnings per share

●Adjusted effective tax rate

We provide these measures as additional information regarding our operating results. We use these non-GAAP measures internally to evaluate our performance and in making financial and operational decisions, including with respect to incentive compensation. We believe that our presentation of these measures provides investors with greater transparency with respect to our results of operations and that these measures are useful for period-to-period comparison of results.

Our non-GAAP financial measure of organic revenue represents revenue growth excluding revenue from acquisitions within the preceding 12 months, the impact of foreign currency, as well as the impact of businesses held-for-sale. Excluding these measures provides more useful period-to-period comparison of revenue results as it excludes the impact of foreign currency exchange rates, which can vary significantly from period to period, and revenue from acquisitions that would not be included in the comparable prior period. Revenues from businesses held-for-sale are excluded from our organic revenue calculation starting on the date they become held-for-sale as those revenues will not be comparative in future periods.

Our non-GAAP financial measures for adjusted gross margin, adjusted operating margin, and adjusted net earnings, in total and on a per share basis, exclude stock-based compensation, which is inclusive of the employer portion of payroll taxes on those stock awards, the costs recognized upon the sale of acquired inventory, amortization of acquisition intangibles, restructuring and restructuring-related costs, and other non-recurring items including non-recurring costs, goodwill and long-lived asset impairments, and gains. Stock-based compensation is excluded from non-GAAP adjusted net earnings because of the nature of this charge, specifically the varying available valuation methodologies, subjective assumptions, variety of award types, and unpredictability of amount and timing of employer related tax obligations. The Company excludes amortization of purchased intangible assets, purchase accounting adjustments, including costs recognized upon the sale of acquired inventory and acquisition-related expenses inclusive of retention costs, severance costs, and changes in fair value contingent consideration, and other non-recurring items including gains or losses on goodwill and long-lived asset impairment charges, and one-time assessments from this measure because they occur as a result of specific events, and are not reflective of our internal investments, the costs of developing, producing, supporting and selling our products, and the other ongoing costs to support our operating structure. We also exclude certain litigation charges which are facts and circumstances specific including costs to resolve litigation and legal settlement (gains and losses). In some cases, these costs may be a result of litigation matters at acquired companies that were not probable, inestimable, or unresolved at the time of acquisition. Costs related to restructuring and restructuring-related activities, including reducing overhead and consolidating facilities, are excluded because we believe they are not indicative of our normal operating costs. Additionally, these amounts can vary significantly from period to period based on current activity. The Company also excludes revenue and expense attributable to businesses held-for-sale in the calculation of our non-GAAP financial measures.

The Company’s non-GAAP adjusted operating margin and adjusted net earnings, in total and on a per share basis, also excludes acquisition related expenses inclusive of the changes in fair value of contingent consideration, gain and losses from investments, as they are not part of our day-to-day operating decisions (excluding our equity method investment in Wilson Wolf as it is certain to be acquired

in the future), certain adjustments to income tax expense, and other non-recurring items. Additionally, gains and losses from investments that are either isolated or cannot be expected to occur again with any predictability are excluded. The Company independently calculates a non-GAAP adjusted tax rate to be applied to the identified non-GAAP adjustments considering the impact of discrete items on these adjustments and the jurisdictional mix of the adjustments. In addition, the tax impact of other discrete and non-recurring charges which impact our reported GAAP tax rate are adjusted from net earnings. We believe these tax items can significantly affect the period-over-period assessment of operating results and not necessarily reflect costs and/or income associated with historical trends and future results.

The Company periodically reassesses the components of our non-GAAP adjustments for changes in how we evaluate our performance, changes in how we make financial and operational decisions, and considers the use of these measures by our competitors and peers to ensure the adjustments are still relevant and meaningful.

Readers are encouraged to review the reconciliations of the adjusted financial measures used in management’s discussion and analysis of the financial condition of the Company to the most directly comparable GAAP financial measures provided within the Company’s Condensed Consolidated Financial Statements.

​

FORWARD-LOOKING INFORMATION AND CAUTIONARY STATEMENTS

This quarterly report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include those regarding the Merger (as defined on the Company’s Annual Report on the 10-K for fiscal 2026), including statements related to the timing of completion of the Merger, or the receipt of necessary approvals to complete the Merger; the significance and timing of costs related to the Merger; the impact on us of litigation or other shareholder action related to the Merger; the effects on us and our shareholders if the Merger is not completed; the Company's expectations as to the effect of changes to accounting policies, the amount of capital expenditures for the remainder of the fiscal year, the source of funding for capital expenditure requirements, the sufficiency of currently available funds for meeting the Company's needs, the impact of fluctuations in foreign currency exchange rates, and expectations regarding gross margin fluctuations, increasing research and development expenses, increasing Selling, general and administrative expenses and income tax rates. These statements involve risks and uncertainties that may affect the actual results of operations. The following important factors, among others, have affected and, in the future, could affect the Company's actual results: integration of newly acquired businesses, the introduction and acceptance of new products, general national and international economic, political, regulatory, and other conditions, increased competition, the reliance on internal manufacturing and related operations, supply chain challenges, the impact of currency exchange rate fluctuations, the recruitment and retention of qualified personnel, the impact of governmental regulation, maintenance of intellectual property rights, credit risk and fluctuation in the market value of the Company's investment portfolio, and unseen delays and expenses related to facility construction and improvements. These forward-looking statements are subject to a number of risks and uncertainties, including, without limitation: (i) the risk that the Merger may not be completed in a timely manner, or at all; (ii) the failure to satisfy the conditions to the consummation of the Merger, including, without limitation, the receipt of regulatory approvals; (iii) unanticipated difficulties or expenditures relating to the Merger; (iv) the effect of the announcement or pendency of the Merger on the Company’s plans, business relationships, operating results and operations; (v) potential difficulties retaining customers, suppliers, distributors and employees as a result of the announcement and pendency of the Merger; (vi) the response of customers, suppliers, distributors and employees to the announcement of the Merger; (vii) risks related to diverting management’s attention from the Company’s ongoing business operations; and (viii) legal proceedings, including those that may be instituted against the Company, its board of directors, its executive officers or others following the announcement of the Merger, as well as the risks and uncertainties. For additional information concerning such factors, see the Company's Annual Report on Form 10-K for fiscal 2026 as filed with the Securities and Exchange Commission and Part II. Item 1A below.

​

Item 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The Company’s exposure to market risk from changes in interest rates and currency exchange rates has not changed materially from its exposure discussed in the Company’s Annual Report on Form 10-K for the year ended June 30, 2026.

​

​

Item 4. CONTROLS AND PROCEDURES

(a) Evaluation of disclosure controls and procedures.

The Company maintains disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)). The Company's management has evaluated, with the participation of its Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of its disclosure controls and procedures as of the end of the period covered in this Quarterly Report on Form 10-Q. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of September 30, 2026, our disclosure controls and procedures were effective.

(b) Changes in internal controls over financial reporting.

There were no changes in the Company's internal control over financial reporting during the first quarter of fiscal 2027 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

As of November 6, 2026, the Company is not a party to any legal proceedings that, individually or in the aggregate, are reasonably expected to have a material adverse effect on the Company's business, results of operations, financial condition or cash flows.

​

Item 1A. RISK FACTORS

During the quarter ended September 30, 2026, there have been no material changes from the risk factors found in Part I, Item 1A, "Risk Factors," of the Company's Annual Report on Form 10-K for the year ended June 30, 2026.

​

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

The Company’s repurchase plan approved by the Board on February 2, 2022, granted management the discretion to mitigate the dilutive effect of stock option exercises. The plan authorized the Company to purchase up to $400 million of the Company’s outstanding common stock. Additionally, the Board approved a new share repurchase plan on April 30, 2025, to replace the previous share repurchase plan, that authorizes the Company to purchase up to $505 million of the Company’s outstanding common stock. As of September 30, 2026, the Company had $363.3 million available to repurchase under our existing plan. While the Merger Agreement is in effect, we are prohibited from repurchasing shares of our common stock, including under the February 2, 2022 and April 30, 2025 share repurchase programs, without the prior written consent of Parent.

​

​​​​​​​​​​​
Period​Total Number of Shares Purchased​​Average Price Paid per Share​Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs​​Maximum Dollar Amount of Shares that May Yet Be Purchased Under the Plans or Programs
July 1 - July 31, 2026​—​$—​—​$363,332,959
August 1 - August 31, 2026​—​​—​—​​363,332,959
September 1 - September 30, 2026​—​​—​—​​363,332,959
July 1 - September 30, 2026​—​​—​—​​​

​

​

​

​

​

ITEM 3. DEFAULT ON SENIOR SECURITIES

None.

​

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

​

Item 5. OTHER INFORMATION

During the quarter ended September 30, 2026, no director or officer of the Company adopted a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as each term is defined in item 408(a) of Regulation S-K.

​

​

Item 6. EXHIBITS

EXHIBIT INDEX

TO

FORM 10-Q

BIO-TECHNE CORPORATION

​

​
Exhibit Number​ ​ ​Description
3.1​Amended and Restated Articles of Incorporation of the Company--incorporated by reference to Exhibit 3.1 of the Company's 8-K dated November 1, 2022*
​
3.2​Fourth Amended and Restated Bylaws of the Company--incorporated by reference to Exhibit 3.1 of the Company’s Form 8-K dated April 27, 2022*
​
31.1​Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
​
31.2​Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
​
32.1​Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
​
32.2​Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
​
101​The following financial statements from the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, formatted in Inline Extensible Business Reporting Language (iXBRL): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Earnings and Comprehensive Income, (iii) the Condensed Consolidated Statements of Cash Flows, (iv) Condensed Consolidated Statements of Stockholders Equity, and (v) Notes to the Condensed Consolidated Financial Statements.
​
104​Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

​

​

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

​

​​​
​​ ​ ​BIO-TECHNE CORPORATION
​​(Company)
​​​
Date: November 12, 2026​/s/ Kim Kelderman
​​Kim Kelderman
​​President and Chief Executive Officer
​​​
Date: November 12, 2026​/s/ James Hippel
​​James Hippel
​​Executive Vice President, Chief Financial Officer

​